SCHEMBL7736093

SCHEMBL7736093

CCCCn1ccc(-c2cc(OC)ccc2OC)c(C(=O)O)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HDAC4 P56524 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
MAPT P10636 2/20 0.42
HPGD P15428 2/20 0.42
ALDH1A1 P00352 2/20 0.42
BRD9 Q9H8M2 2/20 0.41
HTT P42858 1/20 0.41
HIF1A Q16665 1/20 0.41
TNF P01375 2/20 0.40
EDNRB P24530 1/20 0.40
OPRK1 P41145 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA2 P47869 1/20 0.39
GRM2 Q14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7726010 0.88 TOP1 (0.41) KDM4EHSD17B10MAPTHPGDMEN1
SCHEMBL7736063 0.88 ALDH1A1 (0.42) KDM4EHSD17B10HPGDALDH1A1BRD9
SCHEMBL7735552 0.88 BRD9 (0.40) KDM4EHSD17B10MAPTBRD9HTT
SCHEMBL7737859 0.86 MEN1 (0.45) KDM4EHSD17B10HPGDALDH1A1TNF
SCHEMBL7735825 0.84 GFER (0.48) KDM4EHSD17B10MAPTHPGDALDH1A1
SCHEMBL7735824 0.82 GRM2 (0.49) KDM4EHSD17B10BRD9KMT2AGRM2
SCHEMBL7735835 0.80 MTNR1A (0.43) KDM4EHSD17B10HDAC8MAPTHPGD
SCHEMBL7735544 0.78 EDNRA (0.41) GRM2LMNA
SCHEMBL7734365 0.76 ICMT (0.45) KDM4EMAPTALDH1A1TNFOPRK1
SCHEMBL7736088 0.76 PTGER4 (0.44) EDNRBMEN1KMT2AGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK KDM4E 139/4885HSD17B10 470/4885HDAC4 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.